Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
VC-funded Company:


Recida Therapeutics
70 Willow Rd., Suite 200
Menlo Park, CA 94025
Phone: 650-325-5156
http://www.recidatherapeutics.com/

Recida Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections. Recida's lead program, RC-01, is a novel, IND-stage LpxC inhibitor for the treatment of multidrug-resistant gram-negative infections. Recida has licensed development and commercialization rights to RC-01 from FUJIFILM Toyama Chemical Co. Ltd. for all territories outside Japan. Recida intends to a submit an Investigational New Drug application (IND) for RC-01 to the U.S. Food and Drug Administration (FDA) in the first quarter of 2019.

Key Contact
NameTitleE-Mail
James Yigong GeCEO


Funding Events
DateAmountTypeInvestors
02/06/19$8,500,000Series A Frazier Healthcare  
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.